Chief Operating and Financial Officer · Dianthus Therapeutics, Inc. (DNTH)

Jason Ryan

FY2019 is the first fiscal year CompBrief holds for Jason Ryan as a named executive officer of Dianthus Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,940,724

Salary $398,485Stock awards $0Bonus $25,000

1st of 3 named executive officers at Dianthus Therapeutics by FY2019 total.

3 named officers on file for Dianthus Therapeutics, FY2019

Jason Ryan’s pay file — $29

  • 1 fiscal year of pay, line by line
  • DNTH’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Dianthus Therapeutics’s whole pay program stands against its peers

  • Dianthus Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DNTH→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2020 (DEF 14A).

Free

Get Jason Ryan’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jason Ryan compensation by year

Dianthus Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Dianthus Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$398,485
Bonus$25,000
Stock awards$0
Option awards$1,372,861
Non-equity incentive$144,000
Pension and deferred compensation$0
All other$378
Total$1,940,724

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Dianthus Therapeutics, Inc. DEF 14A filed April 24, 2020, accession 0001193125-20-118192, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Dianthus Therapeutics, Inc. filed document, accession 0001193125-20-118192. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option329,379—$6.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Dianthus Therapeutics, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Dianthus Therapeutics’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Jason Ryan · this pageChief Operating and Financial Officer$1,940,724
Jason GardnerPresident and Chief Executive Officer$1,651,001
John DavisHead of Research and Development and Chief Medical Officer$913,521

The full Dianthus Therapeutics compensation record

free company brief

This page is one person within Dianthus Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Dianthus Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Dianthus Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jason Ryan's compensation dossier · One-time report. No refunds.